When.com Web Search

  1. Ads

    related to: xeljanz approved for vitiligo

Search results

  1. Results From The WOW.Com Content Network
  2. Tofacitinib - Wikipedia

    en.wikipedia.org/wiki/Tofacitinib

    The FDA approved only the five-mg, twice-daily dose on the grounds that a higher dose was not considered to have an adequate risk-to-benefit ratio. [34] In September 2020, the FDA approved tofacitinib for the treatment of children and adolescents two years of age and older with active polyarticular course juvenile idiopathic arthritis. [35]

  3. Pfizer Announces FDA Acceptance for Review of Application to ...

    www.aol.com/2013/06/21/pfizer-announces-fda...

    Pfizer Announces FDA Acceptance for Review of Application to Expand Labeling for XELJANZ ® (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis to Include ...

  4. List of therapeutic monoclonal antibodies - Wikipedia

    en.wikipedia.org/wiki/List_of_therapeutic...

    This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.

  5. Pfizer Scores FDA Approval on New Class of RA Drug ... XELJANZ

    www.aol.com/news/2012-11-06-pfizer-scores-fda...

    For premium support please call: 800-290-4726

  6. Pfizer Gets FDA Panel Backing for New Indication for Xeljanz

    www.aol.com/news/pfizer-gets-fda-panel-backing...

    For premium support please call: 800-290-4726 more ways to reach us

  7. Janus kinase 3 inhibitor - Wikipedia

    en.wikipedia.org/wiki/Janus_kinase_3_inhibitor

    The first JAK inhibitor approved for the treatment of rheumatoid arthritis was tofacitinib. It has also shown promising results in other autoimmune disorders. [13] [1] Initially, tofacitinib was thought to be a selective JAK3 inhibitor, but later was found to be a potent inhibitor of JAK1 and JAK2. [2]

  1. Ad

    related to: xeljanz approved for vitiligo